<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00632372</url>
  </required_header>
  <id_info>
    <org_study_id>60015786</org_study_id>
    <nct_id>NCT00632372</nct_id>
  </id_info>
  <brief_title>Cardiac Resynchronization Therapy (CRT) Based Heart Failure Monitoring Study</brief_title>
  <acronym>zLAP</acronym>
  <official_title>CRT-D Based Heart Failure Monitoring Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to collect and analyze electrical measurements, timing, and&#xD;
      signals from a CRT-D device in heart failure patients who either already have an implanted&#xD;
      left atrial pressure sensor or will undergo a simultaneous implantation of a left atrial&#xD;
      pressure sensor and a CRT-D device. These devices may be placed at the same time or&#xD;
      separately (staged procedure) at the discretion of the investigator. A comparison will be&#xD;
      made between the information gathered from the CRT-D system and the information gathered by&#xD;
      the left atrial pressure sensor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-center feasibility study.&#xD;
&#xD;
      .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Determine which heart failure monitoring feature acquired by the CRT device correlates most closely with simultaneously measured left ventricular filling pressure, as measured by left atrial pressure.</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">8</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>HeartPOD™ System with Cardiac Resynchronization Therapy</arm_group_label>
    <description>All patients will receive both a HeartPod device and a CRT-D device.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cardiac Resynchronization Therapy</intervention_name>
    <description>Pacing of the left ventricle to resynchronize ventricular contraction.</description>
    <arm_group_label>HeartPOD™ System with Cardiac Resynchronization Therapy</arm_group_label>
    <other_name>CRT-D</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>HeartPOD™ System</intervention_name>
    <description>Left atrial pressure monitoring.</description>
    <arm_group_label>HeartPOD™ System with Cardiac Resynchronization Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with class III heart failure and a CRT-D device implanted.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 18 and ≤ 85.&#xD;
&#xD;
          -  Have an approved indication per ACC/AHA/HRS guidelines for implantation of a CRT-D.&#xD;
             Alternatively, the patient may already have in place an existing Promote CRT-D or&#xD;
             other SJM CRT device with similar functions, or have a CRT-D device that requires a&#xD;
             generator change. In addition, the patient may be already enrolled in HOMEOSTASIS I or&#xD;
             II and completed the 12-month follow-up.&#xD;
&#xD;
          -  Central venous vascular access.&#xD;
&#xD;
          -  Have a legally marketed right atrial bipolar pacing lead, a right ventricular bipolar&#xD;
             defibrillation lead, and a left ventricular bipolar pacing lead.&#xD;
&#xD;
          -  Demonstrate capability of Valsalva maneuver with airway pressure &gt; 40 mm Hg for ≥10&#xD;
             seconds.&#xD;
&#xD;
          -  The subject and the treating physician agree that the subject is geographically stable&#xD;
             and willing to comply with all required post-procedure follow-up, and that the patient&#xD;
             is capable of correct device use as outlined in the protocol.&#xD;
&#xD;
          -  The subject has been informed of the nature of the study and agrees to its provisions&#xD;
             and has provided written informed consent as approved by the Institutional Review&#xD;
             Board or Ethics Committee of the respective clinical site&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Intractable HF with resting symptoms despite maximal medical therapy (AHA/ACC Stage D)&#xD;
             or active listing for cardiac transplantation (&lt;6 months survival expected).&#xD;
&#xD;
          -  Resting systolic blood pressure &lt; 90 or &gt; 180 mm Hg.&#xD;
&#xD;
          -  Acute Myocardial Infarction (MI), unstable ischemic syndrome within the last 6 weeks.&#xD;
&#xD;
          -  Percutaneous coronary intervention (PCI) or cardiac surgery performed or planned&#xD;
             within ± 6 weeks.&#xD;
&#xD;
          -  Coexisting stenotic valve lesions, vegetations, hypertrophic cardiomyopathy,&#xD;
             amyloidosis or other infiltrative heart disease, constrictive, restrictive disease,&#xD;
             tamponade, or moderate or large pericardial effusion.&#xD;
&#xD;
          -  Subject has a history of deep venous thrombosis or pulmonary embolism within the last&#xD;
             6 months.&#xD;
&#xD;
          -  Surgical correction of congenital heart disease involving atrial septum that will&#xD;
             prevent safe implantation of the SJM HeartPOD ISL.&#xD;
&#xD;
          -  Cerebral Vascular Accident (CVA) or Transient Ischemic Attacks (TIA's) within the last&#xD;
             6 months. History of uncorrected cerebral vascular disease.&#xD;
&#xD;
          -  Atrial or ventricular thrombus, tumor or systemic thromboembolism.&#xD;
&#xD;
          -  Atrial septal defect or clinically significant patent foramen ovale.&#xD;
&#xD;
          -  Life expectancy less than one year from malignancy, primary pulmonary hypertension,&#xD;
             renal, hepatic, or neurological condition, etc.&#xD;
&#xD;
          -  Gastrointestinal bleeding during the last 6 months.&#xD;
&#xD;
          -  Coagulopathy or uninterruptible anticoagulation therapy or unable to take antiplatelet&#xD;
             medications.&#xD;
&#xD;
          -  Creatinine &gt; 2.4 gm/dl (212 µmol/L) at enrollment.&#xD;
&#xD;
          -  Active systemic infection.&#xD;
&#xD;
          -  The subject is currently participating in an investigational drug or another device&#xD;
             study that has not completed the primary endpoint or that clinically interferes with&#xD;
             the current study endpoints.&#xD;
&#xD;
          -  Have a contraindication for an emergency thoracotomy&#xD;
&#xD;
          -  Have a hypersensitivity to a single 1.0mg dose of dexamethasone sodium phosphate or&#xD;
             short term contact with heparin.&#xD;
&#xD;
          -  Positive pregnancy test at enrollment or planning a pregnancy in the next 12 months.&#xD;
&#xD;
          -  Patient is pacemaker dependent, where cessation of pacemaker function consistently&#xD;
             results in syncope or ventricular asystole.&#xD;
&#xD;
          -  Incompatible previously implanted intracardiac devices.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard Troughton, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christchurch Hospital - Christchurch, New Zealand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester Medical Center</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanger Clinic</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Univserity of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 29, 2008</study_first_submitted>
  <study_first_submitted_qc>March 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 10, 2008</study_first_posted>
  <last_update_submitted>October 9, 2020</last_update_submitted>
  <last_update_submitted_qc>October 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

